Sickle cell anemia treatment and compound

Details Sickle cell anemia treatment and compound Sickle cell anemia treatment and compound

1982-06-21

1984-11-13

Waddell, Frederick E.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Recombinant or stably-transformed bacterium encoding one or...

562470, A61K 3119

Patent

active

044825714

ABSTRACT:
A method of treating a person for sickle cell anemia including administering a therapeutically effective dosage of the compound ##STR1## wherein at least one R=Cl, Br, CH.sub.3 or OCH.sub.3 and all the remaining R=H, R'=H or CH.sub.3 and n=1, 2, 3, 4 or 5. Among the preferred species are p-bromobenzyloxyacetic acid, 2-(p-bromobenzyloxy)-2-methylpropionic acid and 3, 4 dichlorobenzyloxyacetic acid. The compound 2-(p-bromobenzyloxy)-2-methylpropionic acid or 3,4 dichlorobenzyloxyacetic acid. The same compound provided as a pharmaceutical in unit dosage form and having properties of resisting the aggregation of hemoglobin in a sickle cell anemia patient.

REFERENCES:
patent: 3262850 (1966-07-01), Jones et al.
patent: 4062974 (1977-12-01), Coirault
National Library of Medicine, "Sickle Cell Anemia", Special Literature Search, Jan. 1970-Jun. 1974; Jul. 1974-Mar. 1978.
"Hemoglobin and the Sickling Cell", by Larry Varner, Pitt Capsule, pp. 4-18.

Affiliated with

Also associated with

Rating

Sickle cell anemia treatment and compound does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sickle cell anemia treatment and compound, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sickle cell anemia treatment and compound will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2360706